An Integrated Smoking Cessation and Alcohol Intervention for Young People

July 2, 2025 updated by: Dr Eva Ho, The Hong Kong Polytechnic University

An Integrated Smoking Cessation and Alcohol Intervention Among Hong Kong Chinese Young People: A Feasibility Randomized Controlled Trial

The specific objectives of this study are to investigate the (1) feasibility, (2) preliminary effectiveness and (3) effect sizes of the integrated smoking cessation and alcohol intervention when compared to standalone smoking cessation (ST) and control among young adults in Hong Kong.

Study Overview

Study Type

Interventional

Enrollment (Actual)

150

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Hongkong, Hong Kong
        • The Hong Kong Polytechnic University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 21 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • aged 18 to 25 years
  • smoked at least one traditional cigarette in the past 30 days
  • consumed at least one alcohol unit (one "alcohol unit" contains 10g of pure alcohol) in the past 30 days
  • speak Cantonese.

Exclusion Criteria:

  • have a compromised mental status and/or communication problems
  • participating in other smoking cessation and/or alcohol interventions

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control arm
Participants will be provided with two leaflets designed by Department of health: one for smoking cessation and another for alcohol abstinence.
Experimental: Standard treatment (ST) arm
Participants will receive a brief smoking cessation intervention based on the "5A" and "5R" models proposed by the World Health Organization. The "STAR" method as quitting skills will also be provided. The "5A" model includes five steps to identify participants who are ready to quit smoking. For those who are ready to quit, a research assistant will assist them to quit using the "STAR" method: Set a quit date within 1 week, Tell the surrounding people that they have planned to quit and solicited their support, Anticipate challenges to quit attempt, and Remove all tobacco products. Otherwise, the "5R" model will be applied to those not yet ready to quit. After "5R" is applied, the research assistant will repeat the assessment of their willingness to quit. The booster interventions will be delivered by the research assistant through follow-ups arranged with the participants via phone.

participants who are ready to quit smoking: a brief smoking cessation intervention based on the "5A" models and "STAR" method as quitting skills.

participants who are not yet ready to quit smoking: a brief smoking cessation intervention based on the "5R" models.

Experimental: Integrated Intervention (II) arm
In addition to the brief smoking cessation intervention based on the "5A" and "5R" models, participants in this arm received brief advice on alcohol use based on the "FRAMES" model. The booster interventions will be delivered by the research assistant through follow-ups arranged with the participants via phone.
brief advice on alcohol use based on the "FRAMES" model and the brief smoking cessation intervention based on the "5A" and "5R" models.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
screening rate
Time Frame: From screening to the end of treatment after 6 months
the number of smokers screened divided by the number of smokers available for screening
From screening to the end of treatment after 6 months
eligibility rate
Time Frame: From screening to the end of treatment after 6 months
the number of eligible smokers divided by the number of screened people
From screening to the end of treatment after 6 months
consent rate
Time Frame: From screening to the end of treatment after 6 months
the number of eligible smokers who agree to participate divided by the number of eligible smokers
From screening to the end of treatment after 6 months
randomization rate
Time Frame: From screening to the end of treatment after 6 months
the number of participants who are randomized divided by the number of eligible smokers who consent to participate
From screening to the end of treatment after 6 months
attendance rate
Time Frame: From screening to the end of treatment after 6 months
the number of participants who complete the intervention divided by the number of participants who are randomized into the treatment arms (ST and II)
From screening to the end of treatment after 6 months
adherence to intervention
Time Frame: From screening to the end of treatment after 6 months
the number of participants in the two treatment arms who practice the skills learned during the intervention divided by the number of participants in the two treatment arms
From screening to the end of treatment after 6 months
retention rate
Time Frame: From screening to the end of treatment after 6 months
the number of participants who remain in the study divided by the number of participants randomized
From screening to the end of treatment after 6 months
completion rate
Time Frame: From screening to the end of treatment after 6 months
the number of participants who complete the questionnaire divided by the number of questionnaires distributed
From screening to the end of treatment after 6 months
missing data
Time Frame: From screening to the end of treatment after 6 months
the percentage of missing data
From screening to the end of treatment after 6 months
adverse events
Time Frame: From screening to the end of treatment after 6 months
unfavorable or unintended events during the study period that were not present at baseline or appear to have worsened since baseline
From screening to the end of treatment after 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Smoking quit rate
Time Frame: From screening to the end of treatment after 6 months
the effect size of II on self-reported and biochemically validated quit rates for smoking at 6 months relative to ST and Control.
From screening to the end of treatment after 6 months
alcohol quit rate
Time Frame: From screening to the end of treatment after 6 months
the effect size of II on self-reported quit rate for alcohol at 6 months relative to ST and Control
From screening to the end of treatment after 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ka Yan Ho, The Hong Kong Polytechnic University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2022

Primary Completion (Actual)

December 31, 2024

Study Completion (Actual)

December 31, 2024

Study Registration Dates

First Submitted

April 13, 2022

First Submitted That Met QC Criteria

November 24, 2022

First Posted (Actual)

November 28, 2022

Study Record Updates

Last Update Posted (Estimated)

July 8, 2025

Last Update Submitted That Met QC Criteria

July 2, 2025

Last Verified

July 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Alcohol Drinking

Clinical Trials on Standard treatment (ST) arm

Subscribe